Pharmacologic Class


More Information

Cardiovascular Disease
Camzyos (mavacamten) A selective allosteric and reversible inhibitor of cardiac myosin Treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Camzyos Approved for Obstructive Hypertrophic Cardiomyopathy
Dermatologic Disorders
Hyftor (sirolimus topical gel) 0.2% mTOR inhibitor immunosuppressant Treatment of facial angiofibroma associated with tuberous sclerosis complex in patients 6 years of age and older. Hyftor Approved for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
Epsolay® (benzoyl peroxide) Oxidizing agent with bactericidal and keratolytic effects Treatment of inflammatory lesions of rosacea. Topical Rosacea Treatment Epsolay Gets FDA Approval
Metabolic Disorders
Vijoice® (alpelisib) Phosphatidylinositol-3-kinase inhibitor Adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum who require systemic therapy. Vijoice Gets Accelerated Approval for PIK3CA-Related Overgrowth Spectrum
Musculoskeletal Disorders
Rinvoq® (upadacitinib) Janus kinase inhibitor Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to 1 or more tumor necrosis factor blockers. Rinvoq Drug Monograph
Neurologic Disorders
Igalmi® (dexmedetomidine) Selective alpha-2a receptor agonist Treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Igalmi Sublingual Film Approved for Agitation With Schizophrenia, Bipolar Disorder
Ultomiris® (ravulizumab-cwvz) Long-acting C5 complement inhibitor Treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. Ultomiris Drug Monograph
Yescarta® (axicabtagene ciloleucel)
CD19-directed genetically modified autologous T cell immunotherapy
Treatment of adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta Drug Monograph
Obstetrics and Gynecology
Vivjoa™ (oteseconazole) Oral inhibitor of fungal CYP51 Treatment of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential. Vivjoa Approved for Recurrent Vulvovaginal Candidiasis
Psychiatric Disorders
Qelbree® (viloxazine)
Selective norepinephrine reuptake inhibitor
Treatment of attention deficit hyperactivity disorder (ADHD) in adults 18 years of age and older. Qelbree Drug Monograph